Lagerstedt and Stenkula receive Novo Seed Grant
This article is over 5 years old, and the information may therefore be outdated. Antidiabetics that also provide cardiovascular benefit is a key unmet need in diabetes treatment. ApoA-l is a protein shown to have both glucose lowering and cholesterol-lowering effects and has been investigated by Jens Lagerstedt and Karin Stenkula for its therapeutic potential. They have now received 2,5 million Da
https://www.ludc.lu.se/article/lagerstedt-and-stenkula-receive-novo-seed-grant - 2026-04-23
